Organovo receives USD 1.7 M grant from NIH

Organovo Holdings, Inc. has announced that it has received a 3-year, USD 1.7 M grant from the National Institutes of Health (“NIH”) to collaboratively study non-alcoholic fatty liver disease (“NAFLD”) with researchers at University of California San Diego School of Medicine (“UC San Diego”). The NIH is the largest public funder of biomedical research in the world.

Deteriorating liver function is a growing and serious public health concern, with an estimated 100 M adults in the U.S. afflicted with NAFLD, while up to 20 M more Americans are projected to have non-alcoholic steatohepatitis (“NASH”).

Organovo’s ExViveTM Human Liver Tissue provides a complex, multicellular, reproducible tissue model with robust architecture that retains metabolic competence and liver-specific function over long durations. Advanced 3D bioprinted models have the potential to significantly impact liver disease research by enabling the discovery of new drugs to treat patients, as well as studying the safety of novel therapeutics in real-world populations.